The mark consists of four shaded oblongs centered above six shaded oblongs of the same size.
Mark For: This trademark registration is intended to cover the categories of
>Color is not claimed as a feature of the mark. The mark consists of four shaded oblongs centered above six shaded oblongs of the same size.
Research | OneLook Acronym Finder |
Serial Number | 88174440 |
Registration Number | 5892912 |
Mark Literal Elements | None |
Mark Drawing Type | 2 - AN ILLUSTRATION DRAWING WITHOUT ANY WORDS(S)/ LETTER(S)/NUMBER(S) |
Mark Type | TRADEMARK. SERVICE MARK |
Standard Character Claim | No |
Register | PRINCIPAL |
Current Location | PUBLICATION AND ISSUE SECTION 2019-09-17 |
Basis | 1(a) |
Class Status | ACTIVE |
Primary US Classes |
|
Primary International Class |
|
Filed Use | No |
Current Use | Yes |
Intent To Use | No |
Filed ITU | Yes |
44D Filed | No |
44E Current | No |
66A Current | No |
Current Basis | No |
No Basis | No |
Attorney Name | Aaron D. Hendelman |
Attorney Docket Number | 48538-TM1003 |
Law Office Assigned | L90 |
Employee Name | RATCLIFFE, ROBERT L |
2018-10-30 | Application Filed |
2019-02-06 | Location: TMEG LAW OFFICE 109 |
2019-02-06 | Status: Live/Pending |
2019-02-06 | Transaction Date |
2019-04-30 | Published |
2019-04-30 | Published for Opposition |
2019-07-24 | Date of First Use |
2019-07-24 | Date of Use In Commerce |
2019-09-17 | Location: PUBLICATION AND ISSUE SECTION |
2019-10-22 | Status: Registered. The registration date is used to determine when post-registration maintenance documents are due. |
2019-10-22 | Trademark Registered |
Party: | TCR2 Therapeutics Inc. |
Address | 100 Binney Street, Suite 710 Cambridge, MASSACHUSETTS UNITED STATES 02142 |
Legal Entity Type | Corporation |
Legal Entity State | DELAWARE |
261127 | Oblongs not used as carriers for words, letters or designs |
IC 005. US 006 018 044 046 051 052. G & S: Biological and pharmaceutical preparations, namely, therapeutic cells, therapeutic proteins and therapeutic nucleic acids for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; pharmaceutical preparations for human use in the nature of biotherapeutics, medicines, and therapeutics, namely, pharmaceutical polypeptides, pharmaceutical antibodies, pharmaceutical nucleic acids, polypeptide-based therapeutics, cell-based therapeutics, RNA-based therapeutics, and DNA-based therapeutics for the treatment and prevention of cancer, inflammation and inflammatory diseases. FIRST USE: 20190724. FIRST USE IN COMMERCE: 20190724
IC 042. US 100 101. G & S: Scientific research in the fields of pharmaceuticals, pharmaceutical research and development, laboratory testing, biotechnology, medicine, biologics, biotherapeutics, biosimilars, cancer treatment, oncology, and therapeutics, namely, polypeptide-based therapeutics, RNA-based therapeutics, and DNA-based therapeutics; providing information on the subject of scientific research in the fields of pharmaceuticals, pharmaceutical research and development, laboratory testing, biotechnology, medicine, biologics, biotherapeutics, biosimilars, cancer treatment, oncology, and therapeutics, namely, polypeptide-based therapeutics, RNA-based therapeutics, and DNA-based therapeutics. FIRST USE: 20161200. FIRST USE IN COMMERCE: 20161200
International Codes: | 5 |
U.S. Codes: | 006,018,044,046,051,052 |
International Codes: | 42 |
U.S. Codes: | 100,101 |
Type Code | Type |
---|---|
CC0000 | Color is not claimed as a feature of the mark. |
CC0000 | Color is not claimed as a feature of the mark. |
Description | Date | Proceeding Number |
---|---|---|
REGISTERED-PRINCIPAL REGISTER | 2019-10-22 | |
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | 2019-09-18 | |
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | 2019-09-17 | |
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2019-09-13 | |
STATEMENT OF USE PROCESSING COMPLETE | 2019-09-12 | 66154 |
EXTENSION 1 GRANTED | 2019-09-12 | 66154 |
CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2019-09-12 | 66154 |
USE AMENDMENT FILED | 2019-09-09 | 66154 |
TEAS STATEMENT OF USE RECEIVED | 2019-09-09 | |
TEAS EXTENSION RECEIVED | 2019-09-09 | |
EXTENSION 1 FILED | 2019-09-09 | 66154 |
NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2019-06-25 | |
PUBLISHED FOR OPPOSITION | 2019-04-30 | |
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2019-04-30 | |
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2019-04-10 | |
LAW OFFICE PUBLICATION REVIEW COMPLETED | 2019-03-26 | 70884 |
APPROVED FOR PUB - PRINCIPAL REGISTER | 2019-03-26 | |
TEAS/EMAIL CORRESPONDENCE ENTERED | 2019-03-21 | 88889 |
TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2019-03-20 | |
CORRESPONDENCE RECEIVED IN LAW OFFICE | 2019-03-20 | 88889 |
NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2019-02-18 | 6325 |
NON-FINAL ACTION WRITTEN | 2019-02-18 | 94057 |
NON-FINAL ACTION E-MAILED | 2019-02-18 | 6325 |
ASSIGNED TO EXAMINER | 2019-02-06 | 94057 |
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | 2019-01-31 | 70884 |
ASSIGNED TO LIE | 2019-01-29 | 70884 |
TEAS VOLUNTARY AMENDMENT RECEIVED | 2019-01-25 | |
NOTICE OF DESIGN SEARCH CODE E-MAILED | 2018-11-15 | |
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2018-11-14 | |
NEW APPLICATION ENTERED IN TRAM | 2018-11-02 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.